Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travelan in a Controlled Human Infection Model for ETEC
NCT05933525Phase 2Completed
- Sponsor
- Immuron Limited
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traveler's diarrhea (TD) and gastroenteritis comparing Travelan with Placebo (2 arms). Primary endpoint: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407. Started May 2023; status: completed.
02
Drugs
IMM-124E
03
Conditions
traveler's diarrhea (TD)gastroenteritis
Beyond the preview
Go deeper on NCT05933525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933525.